Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Pramlintide

MARKETED

amylin analogue (synthetic; short-acting, mealtime s.c.; legacy comparator)

6
graded findings
5
effect domains
Evidence spread
High evidence 5Moderate evidence 0Low evidence 0Very low evidence 1

Pramlintide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pramlintide MARKETED
Weight change Decrease
High evidence

Modest weight loss vs weight gain on insulin alone

Hollander PA, Levy P, Fineman MS, et al. 'Pramlintide as an adjunct to insulin therapy im... Source
PopulationT2D on mealtime insulin, FDA registration trials
Fundingindustry - Amylin Pharmaceuticals (pramlintide developer)
Scope limitsMagnitude far below modern amylin analogues — historical anchor
Comparatorsplacebo + insulin
Pramlintide MARKETED
Weight change Decrease
Very low evidence

Pramlintide, the first approved amylin analogue (US 2005), used as adjunct to insulin in type 1 and insulin-treated type 2 diabetes, produces modest HbA1c reductions...

Pramlintide (Symlin) approval and reviews; DrugBank DB01278; Vascular Health Risk Manag r... Source
Full findingPramlintide, the first approved amylin analogue (US 2005), used as adjunct to insulin in type 1 and insulin-treated type 2 diabetes, produces modest HbA1c reductions and weight loss (reported up to ~1.6 kg). Acts centrally (area postrema) to induce satiety, suppress prandial glucagon, slow gastric emptying and reduce prandial hyperglycaemia.
Populationadults with type 1 and insulin-treated type 2 diabetes (approved adjunct-to-insulin indication)
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsanimal data; human relevance uncertain
Comparatorsplacebo/insulin alone
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pramlintide MARKETED
Glycaemic control Decrease
High evidence

Modest HbA1c reduction as mealtime-insulin adjunct in T1D/T2D

SYMLIN (pramlintide acetate) FDA label, 2015 Source
PopulationT1D/T2D on mealtime insulin, FDA registration trials, ≥6 mo, RCT placebo-controlled
Fundingregulatory agency (FDA/EMA/MHRA/WHO)
Scope limitsMarketed precedent; effect small relative to newer agents
Comparatorsplacebo + insulin
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pramlintide MARKETED
Pharmacology and mechanism Not directional
High evidence

Synthetic human amylin analogue; slows gastric emptying, suppresses glucagon, promotes satiety; t.i.d. mealtime dosing

SYMLIN FDA label 2015 Source
PopulationPharmacology / label
Fundingregulatory agency (FDA/EMA/MHRA/WHO)
Scope limitsFirst marketed amylin analogue — mechanistic precedent for cagrilintide/amycretin/petrelintide
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pramlintide MARKETED
Safety signals Increase
High evidence

Boxed warning for insulin-induced severe hypoglycaemia; requires mealtime-insulin dose reduction

SYMLIN FDA label 2015 Source
PopulationT1D/T2D on mealtime insulin
Fundingregulatory agency (FDA/EMA/MHRA/WHO)
Scope limitsHypoglycaemia is insulin-co-administration effect, not amylin-intrinsic
Comparatorsplacebo + insulin
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pramlintide MARKETED
Gastrointestinal tolerability Increase
High evidence

Nausea most common AE; slows gastric emptying

SYMLIN FDA label 2015 Source
PopulationT1D/T2D registration trials
Fundingregulatory agency (FDA/EMA/MHRA/WHO)
Comparatorsplacebo + insulin